Brain Tumor Diagnosis
Clarity and Confidence
뇌종양 진단에 있어서 Gadovist®는 다른 거대고리형 가돌리늄 기반 조영제(GBCA)에 비해 비교적 높은 조영증강 효과를 나타낼 수 있습니다.4,5
환자에 대한 연구와 생체 내 전임상 연구에 따르면4,5 CNS 영상검사에서 다음과 같은 결과를 보여줍니다.
• 좋은 품질의 영상을 제공합니다.
• 더 높은 조영증강 효과와 더 높은 SNR 및 CNR을 제공하여 악성 종양을 더 쉽게 평가할 수 있습니다.
높은 조영증강 효과는 더 빠르고 일관된 진단을 가능하게 하며, 이는 결국 더 효과적인 치료를 가능하게 하여 환자의 치료 여정을 최적화할 수 있습니다.
MRI Techniques
Getting the Best from Gadovist®
뇌종양 진단, 해부학적 묘사, 치료 반응이나 다발성 경화증 진단을 위해서는 다양한 MRI 검사를 선택할 수 있습니다.
각각은 본질적으로 다른 특성을 가지고 있으며 Gadovist®의 조영증강 효과를 최적화할 수 있습니다.
References
- 1. Rohrer, Martin, et al. "Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths." Investigative Radiology 40.11 (2005): 715-724. Return to content
- 2. Tombach, Bernd, et al. "Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial." European Radiology 18.11 (2008): 2610-2619. Return to content
- 3. Tombach, Bernd, and Walter Heindel. "Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol." European Radiology 12.6 (2002): 1550-1556. Return to content
- 4. Attenberger, Ulrike I., et al. "Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T." Journal of Magnetic Resonance Imaging: An Official Journal of the International Society for Magnetic Resonance in Medicine 31.3 (2010): 549-555. Return to content
- 5. Koenig, M., et al. "Intra-individual, randomised comparison of the MRI contrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read." European Radiology 23.12 (2013): 3287-3295. Return to content
- 6. CM Poser, VV Brinar. "The nature of multiple sclerosis." Clin Neurol Neurosurg 106.3 (2004): 159-171. Return to content
- 7. LLF do Amaral, et al. "Gadolinium-enhanced susceptibility-weighted imaging in multiple sclerosis: optimizing the recognition of active plaques for different MR imaging sequences." AJNR Am J Neuroradiol 40.4 (2019): 614-619. Return to content
- 8. AG Kermode, et al. " Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications." Brain 113.(part 5) (1990): 1477-1489. Return to content
- 9. Liu BP, Rosenberg M, Saverio P, et al. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75). AJR Am J Roentgenol. 2021;217(5):1195-1205. doi:10.2214/AJR.21.25924 Return to content
